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Abstract 
Despite available treatments, a prophylactic HCV vaccine is needed to achieve elimination targets. HCV vaccine devel-
opment has faltered largely because the extreme diversity of the virus limits the protective breadth of vaccine elicited 
antibodies. It is believed that the principle neutralizing epitope in natural infection, HVR1, which is the most variable 
epitope in HCV, mediates humoral immune escape. So far, efforts to circumvent HVR1 interference in the induction 
and function of conserved targeting Ab have failed. Efforts to understand factors contributing to cross-neutralization 
of HVR1 variants have also been limited. Here, following mouse immunizations with two patient-derived HVR1 
peptides, we observe cross-genotype neutralization of variants differing at 15/21 positions. Surprisingly, sequence 
similarity was not associated with cross-neutralization. It appeared neutralization sensitivity was an intrinsic feature of 
each variant, rather than emergent from the immunogen specific Ab response. These findings provide novel insight 
into HVR1-mediated immune evasion, with important implications for HCV vaccine design.
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Introduction
Chronic infection with hepatitis C virus (HCV) is a lead-
ing cause of liver disease, cirrhosis, and hepatocellu-
lar carcinoma, resulting in 475,000 deaths annually [1]. 
Estimates of prevalence based on seropositivity range 
between 1.3 and 2.1%, or between 92 and 149 million 
individuals globally [2]. Though direct-acting antivi-
ral (DAA) therapy is largely curative, only a minority of 
chronic infections (~ 20%) have been diagnosed, with 
even fewer treated (~ 3%) [1]. Persistent challenges in 
screening, diagnosis, access to affordable DAA, and the 
risk for re-infection in vulnerable populations aggravates 
elimination efforts [2]. A prophylactic vaccine for HCV is 
therefore still urgently needed.
The extreme diversity of the virus, with billions of 
related but distinct variants circulating in each infected 
person, has been a major barrier to vaccine develop-
ment [3]. Early candidate vaccines using mammalian 
expressed E2 glycoprotein (E2), a meditator of viral entry 
expressed on the surface of mature virions, were suc-
cessful in inducing protective immunity in chimpanzee 
against homologous challenge [4]. However, progression 
to chronic infection was observed following heterologous 
challenge, with escape mutations subsequently mapped 
to the highly variable N-terminus of E2, termed HVR1 
[4, 5]. Since then, cohort and in vitro analysis has consist-
ently identified HVR1 as the principle target of neutral-
izing antibodies (nAb) in natural infection [6].
Recently, the immunodominant HVR1 has been 
hypothesized to divert the humoral response from con-
served neutralizing epitopes [7, 8]. Some groups have 
therefore sought to elicit cross-neutralizing Ab targeting 
conserved epitopes by amputating HVR1 from E2 immu-
nogens [9]. It was shown that HVR1-deleted E2 was an 
inferior immunogen, failing to elicit even homologous 
nAb following immunization [9]. Variations in HVR1 
have since been implicated in resistance to extra HVR1 
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targeting neutralizing antibodies, underscoring the cru-
cial role of the anti-HVR1 response in any potential HCV 
vaccine [10]. To understand how HCV variation medi-
ates immune escape, global networks of HVR1 cross-
reactivity have been elaborated [11]. Consistent with 
cohort analysis, chimpanzee vaccination, and in  vitro 
neutralization assays, the sequence similarity between 
two HVR1 peptides was predictive of cross-reactivity [5, 
6, 11]. However, cross-reactive pairs with low sequence 
similarity were also observed, indicating a more complex 
relationship between HVR1 variability and immune eva-
sion [11]. Moreover, these studies have not established 
if the observed association between cross-reactivity and 
sequence similarity applies to cross-neutralization. Given 
the critical implications of these questions for HCV 
vaccine design, we sought to clarify these dynamics by 
synthesizing high-Hamming distance HVR1 peptides, 
immunizing mice, and evaluating how sequence simi-
larity associated with cross-neutralization. We hypoth-
esized that intrinsic physicochemical features of HVR1 
sequences contributing to secondary structure might 
influence resistance to neutralization.
Materials and methods
HVR1 shannon variability was mapped by inputting a 
reference alignment of AA 390–410, obtained from The 
Los Alamos Hepatitis C Sequence Database, into the 
Protein Variability server [12, 13]. The patient-derived 
amplicons used to develop the clonal library from which 
immunogens I.1 and I.2 were selected has been previ-
ously described [14]. HVR1 sequences were synthesized 
into peptides using Fmoc chemistry, conjugated to key-
hole limpet hemocyanin via maleimide linkage, and 
mixed at 1:1 ratio with Freunds complete or incomplete 
adjuvant (primary/booster). Mice were subcutaneously 
injected (35  μg peptide + 35  μL adjuvant) at days 0, 28, 
and 38, with terminal bleed via cardiac puncture at day 
48 [4 female, 4–6 weeks old Balb/c per group—protocol 
approved by University Health Network (UHN) Animal 
Care Committee (ACC)]. Mock immunization used adju-
vant with sterile PBS. ELISA and neutralization assays 
were performed as previously described, using heat-
inactivated, group pooled sera at the indicated dilution 
[9]. For physicochemical analysis, the program CRASP 
was used to transform HVR1 sequences into values rep-
resenting secondary structure (HELIXF2), based on fac-
tor analysis [15]. For Hamming Distance and HELIXF2, 
statistical analysis was done using linear regression 
(*P < 0.001). Statistical analysis of neutralization assays 
and ELISA was done by unpaired t test followed by a 
Benjamini–Hochberg false discovery rate (FDR) adjust-
ment for multiple comparisons (Q = 0.05) using Prism8 
[16].
Findings
HVR1 amino acid (AA) variability was visualized as 
Shannon Entropy using a GenBank reference set (Fig. 1a) 
[12]. Low entropy residues correspond to positions under 
purifying selection, and predominate in a putative C-ter-
minal neutralizing epitope (Fig.  1a, blue shading) [6]. 
Using a patient derived clonal library encoding genotype 
1a HVR1 sequences, high-Hamming distance (low pair-
wise sequence similarity) clones I.1 and I.2, differing at 
14/21 AA, were selected for synthesis as 21-mer peptides 
(Fig. 1b). Peptides were then N-terminally conjugated to 
keyhole limpet hemocyanin (KLH) and adjuvanted with 
CFA for mouse immunizations (Fig.  1c). In both vac-
cine groups (I.1, I.2), we observed high-titre (1:100,000) 
immunogen specific Ab following vaccination (Fig.  1d). 
Sera from mock immunized mice (adjuvant only), were 
not reactive by ELISA at any dilution tested (Fig. 1d, right 
panel). Consistent with prior reports of the isolate-spec-
ificity of HVR1 targeting Ab, we did not observe cross-
reactivity between the low sequence similarity I.1 and I.2 
(Fig. 1e).
We then examined if Ab elicited by immunization with 
either KLH-I.1 or KLH-I.2 were neutralizing using a 
multi-isolate panel of HCV-pseudotyped virus (HCVpp) 
representing genotypes 1–6 [17]. We observed cross-
neutralization of HCVpp in both vaccine groups, with 
the infectivity of isolates from genotypes 1a, 1b, 2a, 4a, 
and 5a, significantly inhibited following incubation with 
antisera (Fig.  2a). Remarkably, despite low sequence 
similarity between the two immunizing peptides, simi-
lar patterns of neutralization were observed across 
isolates, implying an intrinsic HVR1 neutralization-
sensitivity phenotype. This contrasts with prior reports 
that HVR1-based immune evasion is a property emer-
gent from the host-specific Ab response [18]. Subsequent 
analysis confirmed that sequence similarity (Hamming 
distance) between vaccine immunogen and HCVpp iso-
late was not significantly associated with sensitivity to 
cross-neutralization (Fig. 2b). We then explored the rela-
tionship between sensitivity to neutralization and the 
integral physicochemical features of each isolates HVR1, 
such as aggregate propensity for α-helical configuration, 
which may directly influence Ab paratope:epitope affin-
ity, using the secondary structure factor HELIXF2 [15]. 
A significant association was observed between second-
ary structure and neutralization sensitivity (Fig.  2c). 
That sensitivity to neutralization by vaccine elicited Ab 
was associated with intrinsic structural properties of the 
viral antigen, but not sequence similarity to the vaccine 
immunogen, further implies the existence of an intrinsic 
neutralization-sensitivity phenotype in HVR1. Intrin-
sic nAB sensitivity-phenotypes have been reported in 
conserved epitopes of HCV, and for HIV tier-2 variants, 
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but to our knowledge this is the first report of neutrali-
zation sensitivity in a variable epitope reflecting inte-
gral physicochemical properties rather than similarity 
to vaccine immunogen [17]. Though tertiary structure, 
glycan shields, and E2-core domain epitopes may influ-
ence HVR1-mediated neutralization, and better predict 
Fig. 1 Monovalent vaccinations elicits high-titre, immunogen specific Ab. a HVR1 variability in a GenBank reference set was visualized by Shannon 
Entropy. Higher entropy corresponds to positions of greater variation. b Candidate immunogens (I.1, 1.2) differ at 14/21 amino acids. Conserved 
positions are indicated by asterisk. c Vaccination protocol for I.1 and 1.2 immunogens. Groups of 4, female Balb/C mice were vaccinated with 
either immunogen I.1, I.2, or adjuvant alone. Mice were bled on day 48, with group sera pooled for subsequent assays. d An ELISA plate was 
coated with immunogen I.1 (left panel), I.2 (middle panel), or both I.1/I.2 (right panel). Heat-inactivated mouse sera from each vaccine group was 
added at the indicated concentrations. e Separate rows of an ELISA plate were coated with either I.1-peptide (unconjugated), KLH (+), or BSA 
(−). Heat-inactivated mouse sera was added at 1:1000 dilution. For both ELISA, the binding of antibody was detected with anti-mouse secondary 
antibody. Averages of data from triplicates are shown. Statistical analysis was done by one-tailed, unpaired t test. *P < 0.001
Fig. 2 Monovalent vaccination elicits cross-nAb to low sequence similarity isolates. a Neutralization of HCVpp pseudotyped with H77.20 (1a), 
UKNP1.4.1 (1a), 1bTO (1b), UKNP2.4.1 (2a), UKNP3.2.1 (3a), UKNP4.1.1 (4a), UKNP5.1.1 (5a), and UKNP6.1.1 (6a) at 1:100 serum dilution. Neutralization 
was normalized to the infectivity of uninhibited virus. Statistical analysis was done by unpaired t test followed by FDR (Q = 0.05) adjustment for 
multiple comparison (*FDR-adjusted P < 0.05). Only significant differences were highlighted. b The residual infectivity of variants treated with 
vaccine sera was plotted against immunogen-virus Hamming distance. Hamming distance was calculated as the number of differing residues in the 
21 AA immunogen alignment. c Residual infectivity was mapped against a secondary structure factor (HELIXF2), calculated for each aligned HVR1 
sequence using the program CRASP. Statistical analysis was done using linear regression, *P < 0.05
Page 4 of 5Mosa et al. Virol J          (2020) 17:140 
neutralization sensitivity, the intrinsic disordering of 
HVR1 poses a challenge to structural models, which is 
reflected in our use of a multivariate analysis accounting 
only for features of secondary structure (HELIXF2) [10, 
15].
Conclusion
Our preliminary findings have critical implications for 
the development of a protective HCV vaccine. Given 
HVR1-mediated immune escape is operative in both nat-
ural infection and following vaccination, the possibility 
that certain HCV variants are resistant to neutralization 
by HVR1-targeting Ab, independent of immunogen or 
prior exposure, suggests that simply increasing the neu-
tralization breadth of vaccine elicited Ab may be inad-
equate for protection from infection [18]. Considering 
HVR1 is the principal neutralizing-epitope, future stud-
ies investigating if particular immunogens, or immuno-
gen combinations, can elicit HVR1-targeting Ab capable 
of neutralizing resistant variants is warranted. Our find-
ings suggest that basing subsequent investigations on 
sequence similarity may be insufficient. We presented a 
crude alternative, using a measure of secondary struc-
ture, that appeared to better approximate sensitivity to 
neutralization. However, novel approaches more accu-
rately accounting for the intrinsic structural features of 
distinct HVR1 variants are needed to resolve this long-
standing challenge in HCV vaccine development.
Abbreviations
HCV: Hepatitis C virus; HVR1: Hypervariable region 1; DAA: Direct acting 
antiviral; E2: Glycoprotein E2; nAb: Neutralizing antibody; AA: Amino acid; KLH: 
Keyhole limpet hemocyanin; CFA: Complete Freunds adjuvant; ELISA: Enzyme 




AM, MA, JF, conceived the study. AM, RU, performed the research. AM 
prepared the manuscript. RU, JT, edited the manuscript. All authors read and 




Sequences used to pseudotype HCVpp H77.20, 1.4.1, 2.4.1, 3.2.1, 4.1.1, 
5.1.1, and are available in GenBank (Accession Nos. NC_038882, KU285161, 
KU285213, KU285218, KU285220, KU285225, KU285227). HVR1 sequences of 
1bTO, I.1, I.2, are available upon request. Sequences used for NPJ constructing 
are available from (https ://hcv.lanl.gov/conte nt/seque nce/NEWAL IGN/align 
.html) with parameters “2008/E2/protein”, or from corresponding author upon 
request. Data and detailed protocol for ELISA and neutralization assays are 
available from author upon request.
Ethics approval
Mouse immunizations were approved by University Health Network (UHN) 




The authors declare that the research was conducted in the absence of any 
commercial or financial relationships that could be construed as a potential 
conflict of interest.
Author details
1 Department of Cell and Systems Biology, University of Toronto, Toronto, 
Canada. 2 Wolfson Centre for Global Virus Infections, University of Nottingham, 
Nottingham, UK. 3 School of Life Sciences, University of Nottingham, Not-
tingham, UK. 4 Department of Molecular Microbiology and Immunology, Saint 
Louis University School of Medicine, St. Louis, USA. 5 Toronto Centre for Liver 
Disease, Toronto General Hospital, Sandra Rotman Centre for Global Health, 
University of Toronto, Toronto, Canada. 
Received: 2 July 2020   Accepted: 28 August 2020
References
 1. Spearman CW, et al. Hepatitis C. Lancet. 2019;394(10207):1451–66. https 
://doi.org/10.1016/S0140 -6736(19)32320 -7.
 2. Manns MP, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 
2017;3(1):1–19. https ://doi.org/10.1038/nrdp.2017.6.
 3. Bailey JR, et al. Approaches, progress, and challenges to hepatitis C vac-
cine development. Gastroenterology. 2019;156(2):418–30. https ://doi.
org/10.1053/j.gastr o.2018.08.060.
 4. Choo QL, et al. Vaccination of chimpanzees against infection by the hepa-
titis C virus. Proc Natl Acad Sci USA. 1994;91(4):1294–8.
 5. Farci P, et al. Prevention of hepatitis C virus infection in chimpanzees by 
hyperimmune serum against the hypervariable region 1 of the envelope 
2 protein. Proc Natl Acad Sci USA. 1996;93(26):15394–9.
 6. Prentoe J, et al. Hypervariable region 1 in envelope protein 2 of hepatitis 
C virus: a linchpin in neutralizing antibody evasion and viral entry. Front 
Immunol. 2018. https ://doi.org/10.3389/fimmu .2018.02146 .
 7. Keck Z, et al. Antibody response to hypervariable region 1 inter-
feres with broadly neutralizing antibodies to hepatitis C virus. J Virol. 
2016;90(6):3112–22. https ://doi.org/10.1128/JVI.02458 -15.
 8. Quadeer AA, et al. Identifying immunologically-vulnerable regions of 
the HCV E2 glycoprotein and broadly neutralizing antibodies that target 
them. Nat Commun. 2019;10(1):1–11. https ://doi.org/10.1038/s4146 
7-019-09819 -1.
 9. Law JLM, et al. Role of the E2 hypervariable region (HVR1) in the Immuno-
genicity of a recombinant hepatitis C virus vaccine. J Virol. 2018. https ://
doi.org/10.1128/JVI.02141 -17.
 10. Johnson J, et al. A recombinant hepatitis C virus genotype 1a E1/
E2 envelope glycoprotein vaccine elicits antibodies that differentially 
neutralize closely related 2a strains through interactions of the N-terminal 
hypervariable region 1 of E2 with scavenger receptor B1. J Virol. 2019. 
https ://doi.org/10.1128/JVI.00810 -19.
 11. Campo DS, et al. Hepatitis C virus antigenic convergence. Sci Rep. 2012. 
https ://doi.org/10.1038/srep0 0267.
 12. Kuiken C, et al. The Los Alamos hepatitis C sequence database. Bioinfor-
matics (Oxford). 2005;21(3):379–84. https ://doi.org/10.1093/bioin forma 
tics/bth48 5.
 13. Garcia-Boronat M, et al. PVS: a web server for protein sequence variability 
analysis tuned to facilitate conserved epitope discovery. Nucl Acids Res. 
2008;36(Web Server issue):W35-41. https ://doi.org/10.1093/nar/gkn21 1.
 14. Donlin MJ, et al. Pretreatment sequence diversity differences in the full-
length hepatitis C virus open reading frame correlate with early response 
to therapy. J Virol. 2007;81(15):8211–24. https ://doi.org/10.1128/JVI.00487 
-07.
 15. Atchley WR, et al. Solving the protein sequence metric problem. Proc Natl 
Acad Sci. 2005;102(18):6395–400. https ://doi.org/10.1073/pnas.04086 
77102 .
Page 5 of 5Mosa et al. Virol J          (2020) 17:140  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 16. Yu X, et al. Statistical approaches to analyzing HIV-1 neutralizing 
antibody assay data. Stat Biopharm Res. 2012;4(1):1–13. https ://doi.
org/10.1080/19466 315.2011.63386 0.
 17. Urbanowicz RA, et al. A diverse panel of hepatitis C virus glycoproteins for 
use in vaccine research reveals extremes of monoclonal antibody neutral-
ization resistance. J Virol. 2015;90(7):3288–301. https ://doi.org/10.1128/
JVI.02700 -15.
 18. Cashman SB, et al. The humoral immune response to HCV: understand-
ing is key to vaccine development. Front Immunol. 2014. https ://doi.
org/10.3389/fimmu .2014.00550 .
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
